Patients with obesity who screened positive for hazardous drinking showed significant reductions in alcohol use after starting GLP-1 receptor agonist therapy, with the heaviest drinkers showing the most improvement.
Large effect sizes on drinking reductionGLP-1 RA treatment was associated with large-magnitude reductions in hazardous drinking scores over ~10 months, with the heaviest drinkers (AUDIT ≥15) showing the most improvement.
What the researchers found
Fourteen patients with overweight/obesity and hazardous drinking (AUDIT score ≥8) were prescribed GLP-1 RAs (semaglutide n=8, tirzepatide n=5, liraglutide n=1) alongside standard dietary and exercise counseling. After a mean of 9.6 months of treatment, both BMI and AUDIT scores decreased significantly.
Patients in the 'very high' AUDIT group (score ≥15) showed more pronounced reductions in drinking scores compared to those in the 'high' group (score 8-14). Effect sizes were large, indicating a substantial magnitude of the GLP-1 RA effect on hazardous drinking behavior.
Why it matters
Anecdotal reports and animal studies have suggested GLP-1 drugs reduce alcohol cravings and consumption, but prospective human data has been limited. This study provides early clinical evidence that GLP-1 receptor agonists may have clinically meaningful effects on hazardous drinking — potentially opening an entirely new therapeutic application for these peptide drugs beyond diabetes and obesity. With alcohol use disorder affecting millions and having limited pharmacotherapy options, this is a significant finding.
How the study worked
Prospective observational study at the University of Chicago Weight Loss Clinic. Patients prescribed GLP-1 RAs for overweight/obesity were screened for hazardous drinking using the AUDIT (Alcohol Use Disorders Identification Test). Those scoring ≥8 were enrolled and reassessed after approximately 9.6 months of treatment. BMI and AUDIT scores were compared pre- and post-treatment.
What this study cannot tell us
This is a very small observational study (n=14) without a control group, so improvements could be partly attributable to the clinical setting, dietary counseling, or natural fluctuation in drinking patterns. Patients were not specifically seeking alcohol treatment, which may introduce selection bias. The AUDIT is a self-report measure subject to social desirability bias. Different GLP-1 drugs were used, making it impossible to determine drug-specific effects. Randomized controlled trials are needed.
How to read the evidence
This is a small prospective observational study without a control group (n=14). While the prospective design and validated outcome measure (AUDIT) add rigor, the tiny sample size and lack of randomization limit causal inference. This is hypothesis-generating evidence that supports the need for randomized trials.
When this study was published
Published in 2025, this is at the forefront of a rapidly emerging research area. Multiple randomized trials of GLP-1 drugs for alcohol use disorder are now being planned or conducted based on accumulating observational evidence like this.
The bigger picture
GLP-1 receptors are found in brain reward circuits, which is why these drugs affect appetite and food cravings. The same reward pathways are involved in alcohol and substance use. Animal studies have consistently shown that GLP-1 agonists reduce alcohol intake, and growing clinical observations support this in humans. If randomized trials confirm these findings, GLP-1 drugs could become the first effective pharmacotherapy for alcohol use disorder that patients are already taking for other reasons — a potential paradigm shift in addiction medicine.
Questions still open
- Do GLP-1 receptor agonists reduce alcohol consumption through the same brain reward pathways they use to reduce food cravings?
- Would a randomized controlled trial of semaglutide specifically for alcohol use disorder show similar benefits?
- Are the alcohol-reducing effects dose-dependent, and do they persist long-term or only while patients are on the medication?
Common questions
Can GLP-1 drugs like Ozempic help people drink less?
Why would a weight loss drug affect alcohol consumption?
Read the original research
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.
Journal of addiction medicine
Citation
King, Andrea C; Wellendorf, Claire; Atkinson, Emily A; de Carvalho, Maria Eduarda Amaral; Fridberg, Daniel J; Pannain, Silvana. (2025). GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.. Journal of addiction medicine. https://doi.org/10.1097/ADM.0000000000001565